Oncodesign Records Positive Profitability for the Second Straight Year and Doubles Its Operating Profit Within the Context of the Global Health Crisis

DIJON, France–(BUSINESS WIRE)–Regulatory News:
ONCODESIGN (ALONC – FR0011766229) (Paris:ALONC), a biopharmaceutical group specialized in precision medicine, announces its FY 2020 financial results and its outlook for 2021 and beyond.
Philippe GENNE, Oncodesign’s Chairman and Chief Executive, says: “Oncodesign has not only proven its resilience and the strength of its economic model, the Company has also shown its agility, its ingenuity and its determination within the context of an unprecedented global public health crisis. Oncodesign has been able to cope with the challenges of a turbulent 2020, generating revenue of €25.5 million, similar to the figure recorded in 2019 – a record year that had seen growth of…